lidocaine has been researched along with Electrocardiogram QT Prolonged in 55 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This positive lidocaine challenge prompted clinical suspicion of long QT syndrome type 3 (LQT3) and early initiation of mexiletine therapy." | 7.76 | Neonatal long QT syndrome type 3 predicted by positive lidocaine challenge. ( Bailey, A; DI Maria, M; Howley, LW; Schaffer, MS, 2010) |
| " However, we found an unusual in utero presentation of intermittent atrioventricular block and ventricular tachycardia (spontaneous or lidocaine-induced) in a fetus and his sibling with LQTS." | 7.74 | In utero onset of long QT syndrome with atrioventricular block and spontaneous or lidocaine-induced ventricular tachycardia: compound effects of hERG pore region mutation and SCN5A N-terminus variant. ( Chahine, M; Chang, CC; Chiu, SN; Christé, G; Ficker, E; Huang, H; Lin, MT; Thériault, O; Wu, MH, 2008) |
| " Minor central nervous system side effects were seen in 2 patients and dermatologic adverse reaction was seen in one patient only." | 6.66 | Efficacy and safety of oral tocainide in refractory ventricular arrhythmia: a preliminary report on an open label study. ( Mahapatra, D; Mahapatra, RK, 1986) |
| "Cocaine can produce arrhythmias either through the production of myocardial ischemia or as a direct result of ion channel alterations." | 6.45 | Management of cocaine-induced cardiac arrhythmias due to cardiac ion channel dysfunction. ( Dargan, PI; Hoffman, RS; Wood, DM, 2009) |
| "Bupropion is an atypical antidepressant often used in the treatment of depression, tobacco cessation, seasonal affective disorder, and off label for ADHD." | 5.72 | Treatment of status epilepticus and prolonged QT after massive intentional bupropion overdose with lidocaine. ( Robinson, S, 2022) |
| "Long QT syndrome is characterized by electrocardiographic appearance of long QT intervals and propensity to polymorphic ventricular tachycardia." | 5.38 | A neonate with long QT syndrome, refractory ventricular arrhythmias, and lidocaine toxicity. ( Montenegro, LM; Naim, M; Nathan, AT; Vetter, VL, 2012) |
| "Sulpiride-induced torsades de pointes is rare." | 5.35 | Long QT syndrome and torsades de pointes induced by acute sulpiride poisoning. ( Chang, JH; Fang, CC; Weng, TI, 2009) |
| "Repeated torsade de pointes tachycardia resulted in hemodynamic compromise and were terminated by defibrillations." | 5.31 | [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects]. ( Bauriedel, G; Lentini, S; Lüderitz, B; Rao, ML; Schröder, R, 2001) |
| " This positive lidocaine challenge prompted clinical suspicion of long QT syndrome type 3 (LQT3) and early initiation of mexiletine therapy." | 3.76 | Neonatal long QT syndrome type 3 predicted by positive lidocaine challenge. ( Bailey, A; DI Maria, M; Howley, LW; Schaffer, MS, 2010) |
| " However, we found an unusual in utero presentation of intermittent atrioventricular block and ventricular tachycardia (spontaneous or lidocaine-induced) in a fetus and his sibling with LQTS." | 3.74 | In utero onset of long QT syndrome with atrioventricular block and spontaneous or lidocaine-induced ventricular tachycardia: compound effects of hERG pore region mutation and SCN5A N-terminus variant. ( Chahine, M; Chang, CC; Chiu, SN; Christé, G; Ficker, E; Huang, H; Lin, MT; Thériault, O; Wu, MH, 2008) |
| "1 We studied the effects of ranolazine, an antianginal agent with promise as an antiarrhythmic drug, on wild-type (WT) and long QT syndrome variant 3 (LQT-3) mutant Na(+) channels expressed in human embryonic kidney (HEK) 293 cells and knock-in mouse cardiomyocytes and used site-directed mutagenesis to probe the site of action of the drug." | 3.73 | Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. ( Fredj, S; Kass, RS; Liu, H; Sampson, KJ, 2006) |
| " Prenatal treatment with beta-adrenergic blocker (propranolol) and digitalis glycosides was prescribed because of suspicion of long QT syndrome occurring with fetal congestive heart failure." | 3.71 | Prenatal diagnosis and treatment of fetal long QT syndrome: a case report. ( Chang, IK; Chow, SN; Hsieh, FJ; Kau, ML; Ko, YH; Lee, CN; Shyu, MK, 2002) |
| " We hypothesized that the use of local dental anesthesia with lidocaine with and without epinephrine is safe and does not result in life-threatening arrhythmias in patients with channelopathies." | 2.90 | Is It Safe for Patients With Cardiac Channelopathies to Undergo Routine Dental Care? Experience From a Single-Center Study. ( Barbosa, SA; Carvalho, CMA; Darrieux, FCC; Grupi, CJ; Hachul, DT; Montano, TCP; Neves, ILI; Neves, RS; Oliveira, ACG; Olivetti, NQS; Pastore, CA; Sacilotto, L; Samesima, N; Santos-Paul, MAD; Scanavacca, MI; Wu, TC, 2019) |
| "Drug-induced long QT syndrome has resulted in many drugs being withdrawn from the market." | 2.82 | Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial. ( Blinova, K; Chan, D; Crumb, WJ; Erato, C; Florian, J; Guo, P; Hong, M; Johannesen, L; Lin, J; Mason, JW; Mutlib, A; Sanabria, C; Stockbridge, N; Stohlman, J; Strauss, DG; Ugander, M; Vicente, J; Waite-Labott, K; Wang, J, 2016) |
| " Minor central nervous system side effects were seen in 2 patients and dermatologic adverse reaction was seen in one patient only." | 2.66 | Efficacy and safety of oral tocainide in refractory ventricular arrhythmia: a preliminary report on an open label study. ( Mahapatra, D; Mahapatra, RK, 1986) |
| "Cocaine can produce arrhythmias either through the production of myocardial ischemia or as a direct result of ion channel alterations." | 2.45 | Management of cocaine-induced cardiac arrhythmias due to cardiac ion channel dysfunction. ( Dargan, PI; Hoffman, RS; Wood, DM, 2009) |
| "Bupropion is an atypical antidepressant often used in the treatment of depression, tobacco cessation, seasonal affective disorder, and off label for ADHD." | 1.72 | Treatment of status epilepticus and prolonged QT after massive intentional bupropion overdose with lidocaine. ( Robinson, S, 2022) |
| "Verapamil treatment was successful in reducing defibrillator discharge frequency of the KCNQ1/TRPM4 dual mutation patient." | 1.72 | In Vitro Drug Screening Using iPSC-Derived Cardiomyocytes of a Long QT-Syndrome Patient Carrying KCNQ1 & TRPM4 Dual Mutation: An Experimental Personalized Treatment. ( Guo, Y; Han, Y; Li, Y; Liang, X; Lu, Y; Sang, W; Tang, B; Wang, F; Wang, L; Xiaokereti, J; Xing, Q; Zhang, J; Zhang, L; Zhou, X; Zukela, T, 2022) |
| "We present a case of seizure activity in a woman in whom EKG led to a diagnosis of intermittent monomorphic and polymorphic ventricular tachycardia (torsades de pointes), highlighting the need for careful consideration of alternative causes of seizures, even in patients with known epilepsy." | 1.46 | Ventricular tachycardia and prolonged QT interval presenting as seizure-like activity. ( Mitchell, SH; Morris, SC; Wentlandt, M, 2017) |
| "No arrhythmia was induced by lidocaine." | 1.40 | Procainamide and lidocaine produce dissimilar changes in ventricular repolarization and arrhythmogenicity in guinea-pig. ( Osadchii, OE, 2014) |
| "Long QT syndrome is characterized by electrocardiographic appearance of long QT intervals and propensity to polymorphic ventricular tachycardia." | 1.38 | A neonate with long QT syndrome, refractory ventricular arrhythmias, and lidocaine toxicity. ( Montenegro, LM; Naim, M; Nathan, AT; Vetter, VL, 2012) |
| "Sulpiride-induced torsades de pointes is rare." | 1.35 | Long QT syndrome and torsades de pointes induced by acute sulpiride poisoning. ( Chang, JH; Fang, CC; Weng, TI, 2009) |
| "Lidocaine was substituted for oral mexiletine, and esmolol for propranolol." | 1.34 | Neonatal life-threatening arrhythmia responding to lidocaine, a probable LQTS3. ( Antúnez Jiménez, MI; Betrián Blasco, P; Falcón González, LH; Suárez Cabrera, P, 2007) |
| " They have apparently safe cardiac safety profiles in both therapeutic and supratherapeutic doses, but recently the Federal Drug Administration has issued a caution regarding ziprasidone use in combination with other drugs that are known to prolong the QTc interval." | 1.32 | Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. ( Biswas, AK; Mayes, KL; Morris-Kukoski, CL; Zabrocki, LA, 2003) |
| "The congenital long QT syndrome is an inherited disorder characterized by a delay in cardiac repolarization, leading to lethal cardiac arrhythmias such as torsade de pointes." | 1.31 | Selective block of late currents in the DeltaKPQ Na(+) channel mutant by pilsicainide and lidocaine with distinct mechanisms. ( Arita, M; Kaku, T; Kitabatake, A; Makita, N; Ono, K, 2000) |
| "Repeated torsade de pointes tachycardia resulted in hemodynamic compromise and were terminated by defibrillations." | 1.31 | [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects]. ( Bauriedel, G; Lentini, S; Lüderitz, B; Rao, ML; Schröder, R, 2001) |
| "Torsade de pointes (TdP) syncopal episodes were almost invariably precipitated by emotional stress or menstruation in a 17-year-old girl." | 1.28 | Role of early afterdepolarization in familial long QTU syndrome and torsade de pointes. ( Liu, WY; Zheng, LR; Zhou, JT, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (5.45) | 18.7374 |
| 1990's | 5 (9.09) | 18.2507 |
| 2000's | 24 (43.64) | 29.6817 |
| 2010's | 14 (25.45) | 24.3611 |
| 2020's | 9 (16.36) | 2.80 |
| Authors | Studies |
|---|---|
| Ola, O | 1 |
| Gharacholou, SM | 1 |
| Del-Carpio Munoz, F | 1 |
| Bains, S | 1 |
| Lador, A | 1 |
| Neves, R | 1 |
| Bos, JM | 2 |
| Giudicessi, JR | 2 |
| Cannon, BC | 1 |
| Ackerman, MJ | 3 |
| Newlon, C | 1 |
| Etheridge, SP | 1 |
| Robinson, S | 1 |
| Wang, F | 1 |
| Han, Y | 1 |
| Sang, W | 1 |
| Wang, L | 2 |
| Liang, X | 1 |
| Xing, Q | 1 |
| Guo, Y | 1 |
| Zhang, J | 1 |
| Zhang, L | 1 |
| Zukela, T | 1 |
| Xiaokereti, J | 1 |
| Lu, Y | 1 |
| Zhou, X | 1 |
| Tang, B | 1 |
| Li, Y | 1 |
| Stutzman, MJ | 1 |
| Gao, X | 1 |
| Kim, M | 1 |
| Ye, D | 2 |
| Zhou, W | 1 |
| Tester, DJ | 1 |
| Shannon, K | 1 |
| Ke, Z | 1 |
| Li, C | 1 |
| Bai, G | 1 |
| Tan, L | 1 |
| Wang, J | 2 |
| Zhou, M | 1 |
| Zhou, J | 1 |
| Chen, SY | 1 |
| Dong, X | 1 |
| Hasebe, H | 1 |
| Yokoya, T | 1 |
| Murakoshi, N | 1 |
| Kurebayashi, N | 1 |
| Zhu, E | 1 |
| Gabriele, M | 1 |
| Nguyen, MT | 1 |
| Anderson, HN | 1 |
| Kapplinger, JD | 1 |
| Meskill, JM | 1 |
| Oliveira, ACG | 1 |
| Neves, ILI | 1 |
| Sacilotto, L | 1 |
| Olivetti, NQS | 1 |
| Santos-Paul, MAD | 1 |
| Montano, TCP | 1 |
| Carvalho, CMA | 1 |
| Wu, TC | 1 |
| Grupi, CJ | 1 |
| Barbosa, SA | 1 |
| Pastore, CA | 1 |
| Samesima, N | 1 |
| Hachul, DT | 1 |
| Scanavacca, MI | 1 |
| Neves, RS | 1 |
| Darrieux, FCC | 1 |
| Osadchii, OE | 1 |
| Cuneo, BF | 2 |
| Strasburger, JF | 2 |
| Yu, S | 1 |
| Horigome, H | 1 |
| Hosono, T | 1 |
| Kandori, A | 1 |
| Wakai, RT | 2 |
| Johannesen, L | 2 |
| Vicente, J | 2 |
| Mason, JW | 2 |
| Erato, C | 1 |
| Sanabria, C | 1 |
| Waite-Labott, K | 1 |
| Hong, M | 1 |
| Lin, J | 1 |
| Guo, P | 1 |
| Mutlib, A | 1 |
| Crumb, WJ | 1 |
| Blinova, K | 1 |
| Chan, D | 1 |
| Stohlman, J | 1 |
| Florian, J | 1 |
| Ugander, M | 1 |
| Stockbridge, N | 1 |
| Strauss, DG | 2 |
| Crimmins, S | 1 |
| Vashit, S | 1 |
| Doyle, L | 1 |
| Harman, C | 1 |
| Turan, O | 1 |
| Turan, S | 1 |
| Wentlandt, M | 1 |
| Morris, SC | 1 |
| Mitchell, SH | 1 |
| Hosseini, M | 1 |
| Sager, PT | 1 |
| Pueyo, E | 1 |
| Owczuk, R | 1 |
| Wujtewicz, MA | 1 |
| Sawicka, W | 1 |
| Piankowski, A | 1 |
| Polak-Krzeminska, A | 1 |
| Morzuch, E | 1 |
| Wujtewicz, M | 1 |
| Wood, DM | 1 |
| Dargan, PI | 1 |
| Hoffman, RS | 1 |
| Lin, MT | 1 |
| Wu, MH | 2 |
| Chang, CC | 2 |
| Chiu, SN | 1 |
| Thériault, O | 1 |
| Huang, H | 1 |
| Christé, G | 1 |
| Ficker, E | 1 |
| Chahine, M | 3 |
| Dolenska, S | 1 |
| Howley, LW | 1 |
| DI Maria, M | 1 |
| Bailey, A | 1 |
| Schaffer, MS | 1 |
| Chang, JH | 1 |
| Weng, TI | 1 |
| Fang, CC | 1 |
| Takaya, T | 1 |
| Okamoto, M | 1 |
| Yodoi, K | 1 |
| Hata, K | 1 |
| Kijima, Y | 1 |
| Nakajima, H | 1 |
| Nishikawa, Y | 1 |
| Kita, T | 1 |
| Ito, M | 1 |
| Seo, T | 1 |
| Kawashima, S | 1 |
| Braam, SR | 1 |
| Tertoolen, L | 1 |
| van de Stolpe, A | 1 |
| Meyer, T | 1 |
| Passier, R | 1 |
| Mummery, CL | 1 |
| Komarlu, R | 1 |
| Beerman, L | 1 |
| Freeman, D | 1 |
| Arora, G | 1 |
| Nathan, AT | 1 |
| Naim, M | 1 |
| Montenegro, LM | 1 |
| Vetter, VL | 1 |
| Song, W | 1 |
| Xiao, Y | 1 |
| Chen, H | 1 |
| Ashpole, NM | 1 |
| Piekarz, AD | 1 |
| Ma, P | 1 |
| Hudmon, A | 1 |
| Cummins, TR | 1 |
| Shou, W | 1 |
| Hoffmann, C | 1 |
| Falzone, E | 1 |
| Augé, M | 1 |
| Dinanian, S | 1 |
| Mercier, FJ | 1 |
| Takagi, M | 1 |
| Doi, A | 1 |
| Takeuchi, K | 1 |
| Yoshikawa, J | 1 |
| Chang, IK | 1 |
| Shyu, MK | 1 |
| Lee, CN | 1 |
| Kau, ML | 1 |
| Ko, YH | 1 |
| Chow, SN | 1 |
| Hsieh, FJ | 1 |
| Biswas, AK | 1 |
| Zabrocki, LA | 1 |
| Mayes, KL | 1 |
| Morris-Kukoski, CL | 1 |
| Ovadia, M | 1 |
| Zhao, H | 1 |
| Petropulos, T | 1 |
| Schneider, J | 1 |
| Keller, DI | 1 |
| Acharfi, S | 2 |
| Delacrétaz, E | 1 |
| Benammar, N | 1 |
| Rotter, M | 1 |
| Pfammatter, JP | 1 |
| Fressart, V | 1 |
| Guicheney, P | 1 |
| Chauhan, VS | 1 |
| Krahn, AD | 1 |
| Klein, GJ | 1 |
| Skanes, AC | 1 |
| Yee, R | 1 |
| Chiang, FT | 1 |
| Wang, JK | 1 |
| Sung, TC | 1 |
| Kameyama, E | 1 |
| Ito, Y | 1 |
| Ito, J | 1 |
| Saito, K | 1 |
| Murakami, N | 1 |
| Horinouchi, T | 1 |
| Kato, M | 1 |
| Fredj, S | 1 |
| Sampson, KJ | 1 |
| Liu, H | 1 |
| Kass, RS | 4 |
| Betrián Blasco, P | 1 |
| Antúnez Jiménez, MI | 1 |
| Falcón González, LH | 1 |
| Suárez Cabrera, P | 1 |
| Sabir, IN | 1 |
| Killeen, MJ | 1 |
| Goddard, CA | 1 |
| Thomas, G | 1 |
| Gray, S | 1 |
| Grace, AA | 1 |
| Huang, CL | 1 |
| Surber, R | 1 |
| Hensellek, S | 1 |
| Prochnau, D | 1 |
| Werner, GS | 1 |
| Benndorf, K | 1 |
| Figulla, HR | 1 |
| Zimmer, T | 1 |
| Strickland, RA | 1 |
| Stanton, MS | 1 |
| Olsen, KD | 1 |
| An, RH | 1 |
| Bangalore, R | 1 |
| Rosero, SZ | 1 |
| Kambouris, NG | 2 |
| Nuss, HB | 2 |
| Johns, DC | 2 |
| Tomaselli, GF | 2 |
| Marban, E | 2 |
| Balser, JR | 2 |
| Ono, K | 1 |
| Kaku, T | 1 |
| Makita, N | 1 |
| Kitabatake, A | 1 |
| Arita, M | 1 |
| Benhorin, J | 2 |
| Taub, R | 1 |
| Goldmit, M | 1 |
| Kerem, B | 2 |
| Windman, I | 1 |
| Medina, A | 1 |
| Macua Biurrun, P | 1 |
| Telletxea Benguria, S | 1 |
| Aguirre Aras, J | 1 |
| Larrazabal Bilbao, R | 1 |
| Aguilera Celorrio, L | 1 |
| Abriel, H | 1 |
| Wehrens, XH | 1 |
| Lentini, S | 1 |
| Rao, ML | 1 |
| Schröder, R | 1 |
| Lüderitz, B | 1 |
| Bauriedel, G | 1 |
| Zhou, JT | 1 |
| Zheng, LR | 1 |
| Liu, WY | 1 |
| Inoue, H | 1 |
| Sugimoto, T | 1 |
| Mahapatra, RK | 1 |
| Mahapatra, D | 1 |
| Popov, SV | 1 |
| Chekhov, AM | 1 |
| Pekarskiĭ, VV | 1 |
| Gimrikh, EO | 1 |
| Savenkov, GG | 1 |
| Nielsen, H | 1 |
| Badskjaer, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies[NCT03182777] | 31 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| Fetal Electrophysiologic Abnormalities in High-risk Pregnancies Associated With Fetal Demise[NCT03775954] | 200 participants (Anticipated) | Observational | 2018-07-01 | Recruiting | |||
| Clinical ECG Study to Evaluate Electrophysiological Effects of Potential QT Prolonging Drugs With Novel ECG Biomarkers With Exposure-Response Analysis[NCT05716854] | Phase 1 | 44 participants (Actual) | Interventional | 2023-03-21 | Completed | ||
| Five Period Crossover Study of the Ability of Late Sodium or Calcium Current Block (Mexiletine, Lidocaine, or Diltiazem) to Balance the Electrocardiographic Effects of hERG Potassium Current Block (Dofetilide or Moxifloxacin)[NCT02308748] | Phase 1 | 22 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled Single-Dose, Five Period Crossover Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects[NCT01873950] | Phase 1 | 22 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Analgesic Effect of Perioperative Systemic Lidocaine in Patients Undergoing Unilateral Mastectomy Surgery[NCT00913003] | Phase 4 | 22 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to PI terminated employment with the University) | ||
| Long QT Syndrome-Population Genetics and Cardiac Studies[NCT00005176] | 2,125 participants (Actual) | Observational | 1985-08-31 | Completed | |||
| Efficacy of Ranolazine in LQT3 Patients[NCT01648205] | Phase 2 | 25 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evening dose (moxifloxacin+diltiazem) versus afternoon dose (diltiazem alone). (NCT02308748)
Timeframe: 5 weeks
| Intervention | ms (Mean) |
|---|---|
| Moxifloxacin Alone | 29.9 |
| Moxifloxacin + Diltiazem | 31.3 |
After 3rd dose of mexiletine or lidocaine (evening dose) on treatment day when combined with dofetilide to evening dose on dofetilide alone day. (NCT02308748)
Timeframe: 5 weeks
| Intervention | ms (Mean) | |
|---|---|---|
| Placebo corrected change from baseline in QTc | Placebo corrected change from baseline in J-Tpeakc | |
| Dofetilide + Lidocaine | 18 | 3.5 |
| Dofetilide + Mexiletine | 20.4 | 0.8 |
| Dofetilide Alone | 37.9 | 24.0 |
Different post-dose time-points employ different techniques for altering heart rate (leg raises and postural maneuvers). Using the measurements from all the time-points of postural maneuvers, the QT/RR relationship was modeled as a linear relationship between the square root of RR in seconds and QT in seconds and computed on a by subject, treatment and time-point basis. The change in the QT and heart rate relationship was assessed as the difference (mean and 95% CI) between the slopes from the models for each drug vs. placebo. (NCT01873950)
Timeframe: 24 hours
| Intervention | ratio (Mean) |
|---|---|
| Ranolazine 1500mg | 0.01 |
| Dofetilide 500mcg | 0.06 |
| Verapamil HCl 120 mg | 0.02 |
| Quinidine Sulfate 400mg | 0.11 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in spatial QRS-T angle for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | degrees per ng/ml (Mean) |
|---|---|
| Dofetilide 500mcg | -3.9 |
| Verapamil HCl 120 mg | 0.4 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in spatial QRS-T angle for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | degrees per mcg/ml (Mean) |
|---|---|
| Ranolazine 1500mg | -1.0 |
| Quinidine Sulfate 400mg | 2.7 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in ventricular gradient for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | mV.ns per ng/ml (Mean) |
|---|---|
| Dofetilide 500mcg | 4.0 |
| Verapamil HCl 120 mg | 1.2 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in ventricular gradient for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | mV.ns per mcg/ml (Mean) |
|---|---|
| Ranolazine 1500mg | -0.7 |
| Quinidine Sulfate 400mg | 1.6 |
Compute maximum mean placebo, and baseline-adjusted change for: spatial QRS-T angle (degrees) (NCT01873950)
Timeframe: 24 hours
| Intervention | degrees (Least Squares Mean) |
|---|---|
| Ranolazine 1500mg | -2.2 |
| Dofetilide 500mcg | -4.9 |
| Verapamil HCl 120 mg | -2.4 |
| Quinidine Sulfate 400mg | 3.9 |
Compute maximum mean placebo, and baseline-adjusted change for: ventricular gradient (mV*ms). (NCT01873950)
Timeframe: 24 hours
| Intervention | mV*ms (Least Squares Mean) |
|---|---|
| Ranolazine 1500mg | 2.5 |
| Dofetilide 500mcg | 4.8 |
| Verapamil HCl 120 mg | 4.2 |
| Quinidine Sulfate 400mg | 6.0 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in QTc for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | ms per ng/ml (Mean) | ||||
|---|---|---|---|---|---|
| Change in PR | Change in QTc | Change in QRS | Change in J-Tpeakc | Change in Tpeak-Tend | |
| Dofetilide 500mcg | -0.5 | 73.6 | 0.2 | 39.1 | 34.4 |
| Verapamil HCl 120 mg | 28.7 | 3.9 | 0.3 | -0.7 | 3.6 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in QTc for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | ms per mcg/ml (Mean) | ||||
|---|---|---|---|---|---|
| Change in PR | Change in QTc | Change in QRS | Change in J-Tpeakc | Change in Tpeak-Tend | |
| Quinidine Sulfate 400mg | 3.0 | 78.9 | 0.4 | 26.1 | 51.2 |
| Ranolazine 1500mg | 4.2 | 12.0 | 0.8 | 0.7 | 10.0 |
Compute maximum mean placebo, and baseline-adjusted change for: PR (ms), QRS (ms), J-Tpeak (ms), Tpeak-Tend (ms) and QTc (ms) (NCT01873950)
Timeframe: 24 hours
| Intervention | ms (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Change in PR interval | Change in QRS duration | Change in J-Tpeakc | Change in Tpeak-Tend | Change in QTc | |
| Dofetilide 500mcg | 2.3 | 1.1 | 39.5 | 40.0 | 79.3 |
| Quinidine Sulfate 400mg | 5.1 | 2.1 | 29.1 | 49.8 | 78.1 |
| Ranolazine 1500mg | 6.5 | 2.7 | 3.3 | 8.8 | 12.6 |
| Verapamil HCl 120 mg | 32.1 | 2.6 | -2.4 | 4.8 | 5.2 |
Total IV hydromorphone administered during surgery to 24 hours post surgery (NCT00913003)
Timeframe: 24 hour
| Intervention | miligrams (Mean) |
|---|---|
| Placebo | 2.33 |
| Lidocaine | 1.5 |
(NCT00913003)
Timeframe: 7 days
| Intervention | Participants (Number) |
|---|---|
| Placebo | 0 |
| Lidocaine | 0 |
Nausea at any time during the post operative period for 48 hours (NCT00913003)
Timeframe: Immediate post operative to 48 hours
| Intervention | Participants (Number) |
|---|---|
| Placebo | 11 |
| Lidocaine | 11 |
Change in QTc at 6 months on ranolazine vs. at 1 month on placebo. This was prespecified outcome. (NCT01648205)
Timeframe: 1 month to 6 months
| Intervention | miliseconds (Mean) |
|---|---|
| Placebo | 504 |
| Ranolazine at 6 Months | 501 |
Change in QTc at 2 months on ranolazine vs. at 1 month on placebo. This was prespecified outcome. (NCT01648205)
Timeframe: 1 month to 2 months
| Intervention | miliseconds (Mean) |
|---|---|
| Placebo | 503 |
| Ranolazine at 2 Months | 497 |
2 reviews available for lidocaine and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Management of cocaine-induced cardiac arrhythmias due to cardiac ion channel dysfunction.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cocaine; Cocaine-Related D | 2009 |
Prolonged QT syndrome: perioperative management.
Topics: Adolescent; Adult; Atropine; Carcinoma, Squamous Cell; Child; Female; Glossectomy; Heart Arrest; Hum | 1993 |
5 trials available for lidocaine and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Is It Safe for Patients With Cardiac Channelopathies to Undergo Routine Dental Care? Experience From a Single-Center Study.
Topics: Adolescent; Adult; Aged; Anesthetics, Local; Brugada Syndrome; Channelopathies; Contraindications, P | 2019 |
Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.
Topics: Adult; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cross-Over Studies; Diltiazem; Drug Therapy | 2016 |
Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.
Topics: Adult; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cross-Over Studies; Diltiazem; Drug Therapy | 2016 |
Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.
Topics: Adult; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cross-Over Studies; Diltiazem; Drug Therapy | 2016 |
Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.
Topics: Adult; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cross-Over Studies; Diltiazem; Drug Therapy | 2016 |
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go | 2016 |
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go | 2016 |
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go | 2016 |
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go | 2016 |
The effect of intravenous lidocaine on QT changes during tracheal intubation.
Topics: Adult; Anesthetics, Local; Blood Pressure; Double-Blind Method; Electrocardiography; Female; Heart R | 2008 |
Efficacy and safety of oral tocainide in refractory ventricular arrhythmia: a preliminary report on an open label study.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Central Nervous Sy | 1986 |
48 other studies available for lidocaine and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Massive Discordant T-Wave Alternans and Imminent Torsades de Pointes: The "Elephant in the Room".
Topics: Anti-Arrhythmia Agents; Chest Pain; Cocaine-Related Disorders; Electrocardiography; Female; Humans; | 2021 |
Role of chronic continuous intravenous lidocaine in the clinical management of patients with malignant type 3 long QT syndrome.
Topics: Anti-Arrhythmia Agents; Cardiac Conduction System Disease; Female; Humans; Infant; Infant, Newborn; | 2022 |
Intravenous lidocaine in malignant long QT type 3: A bridge over troubled waters.
Topics: Administration, Intravenous; Electrocardiography; Humans; Lidocaine; Long QT Syndrome | 2022 |
Treatment of status epilepticus and prolonged QT after massive intentional bupropion overdose with lidocaine.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Bupropion; Cardiotoxicity; Drug Overdose; Fema | 2022 |
In Vitro Drug Screening Using iPSC-Derived Cardiomyocytes of a Long QT-Syndrome Patient Carrying KCNQ1 & TRPM4 Dual Mutation: An Experimental Personalized Treatment.
Topics: Arrhythmias, Cardiac; Drug Evaluation, Preclinical; Humans; Induced Pluripotent Stem Cells; KCNQ1 Po | 2022 |
Functional characterization and identification of a therapeutic for a novel SCN5A-F1760C variant causing type 3 long QT syndrome refractory to all guideline-directed therapies.
Topics: Anti-Arrhythmia Agents; Humans; Infant; Lidocaine; Long QT Syndrome; Mexiletine; NAV1.5 Voltage-Gate | 2023 |
KCNH2 mutation c.3099_3112del causes congenital long QT syndrome type 2 with gender differences.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Female; Humans; Lidocaine; Long QT Syndrom | 2023 |
Pilsicainide Administration Unmasks a Phenotype of Brugada Syndrome in a Patient with Overlap Syndrome due to the E1784K SCN5A Mutation.
Topics: Adult; Anti-Arrhythmia Agents; Brugada Syndrome; Electrocardiography; Humans; Lidocaine; Long QT Syn | 2020 |
The Use of Intravenous Lidocaine in the Setting of Chronic Dofetilide Overdose: A Case Report.
Topics: Alcoholism; Drug Overdose; Electrocardiography; Humans; Lidocaine; Long QT Syndrome; Substance Withd | 2022 |
Lidocaine attenuation testing: An in vivo investigation of putative LQT3-associated variants in the SCN5A-encoded sodium channel.
Topics: Adolescent; Cardiac Conduction System Disease; DNA Mutational Analysis; Electrocardiography; Female; | 2017 |
Procainamide and lidocaine produce dissimilar changes in ventricular repolarization and arrhythmogenicity in guinea-pig.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Femal | 2014 |
In utero diagnosis of long QT syndrome by magnetocardiography.
Topics: Anti-Arrhythmia Agents; Cohort Studies; Electrocardiography; Female; Fetal Diseases; Genetic Associa | 2013 |
A multidisciplinary approach to prenatal treatment of congenital long QT syndrome.
Topics: Adult; Electrocardiography; Female; Heart Rate Determination; Humans; Lidocaine; Long QT Syndrome; M | 2017 |
Ventricular tachycardia and prolonged QT interval presenting as seizure-like activity.
Topics: Adult; Alcoholism; Anti-Arrhythmia Agents; Anticonvulsants; Diuretics; Electrocardiography; Emergenc | 2017 |
In utero onset of long QT syndrome with atrioventricular block and spontaneous or lidocaine-induced ventricular tachycardia: compound effects of hERG pore region mutation and SCN5A N-terminus variant.
Topics: Age of Onset; Anti-Arrhythmia Agents; Atrioventricular Block; ERG1 Potassium Channel; Ether-A-Go-Go | 2008 |
Intraoperative cardiac arrest in acquired long QT syndrome.
Topics: Adult; Anesthesia, General; Anesthetics, Local; Epinephrine; Female; Heart Arrest; Humans; Intraoper | 2009 |
Neonatal long QT syndrome type 3 predicted by positive lidocaine challenge.
Topics: Anti-Arrhythmia Agents; Bradycardia; Electrocardiography; Female; Humans; Infant, Newborn; Lidocaine | 2010 |
Long QT syndrome and torsades de pointes induced by acute sulpiride poisoning.
Topics: Dopamine Antagonists; Female; Humans; Lidocaine; Long QT Syndrome; Magnesium Sulfate; Sulpiride; Tor | 2009 |
Torsades de Pointes with QT prolongation related to donepezil use.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Colitis; Donepezil; Electrocardiogr | 2009 |
Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes.
Topics: Animals; Cell Line; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; E | 2010 |
Fetal and neonatal presentation of long QT syndrome.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Electrocardiography; ERG1 Potassium Channel; Et | 2012 |
A neonate with long QT syndrome, refractory ventricular arrhythmias, and lidocaine toxicity.
Topics: Amiodarone; Anesthetics, Local; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; DNA Mutational A | 2012 |
The human Nav1.5 F1486 deletion associated with long QT syndrome leads to impaired sodium channel inactivation and reduced lidocaine sensitivity.
Topics: Anesthetics, Local; Animals; Animals, Newborn; Anti-Arrhythmia Agents; Drug Tolerance; HEK293 Cells; | 2012 |
Long QT syndrome, amiodarone use, and the mechanism underlying lidocaine toxicity.
Topics: Anesthetics, Local; Anti-Arrhythmia Agents; Humans; Lidocaine; Long QT Syndrome; Male; Tachycardia, | 2012 |
Pilsicanide-induced marked T wave alternans and ventricular fibrillation in a patient with Brugada syndrome.
Topics: Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Electrocardiography; Humans; Lidocaine; Long QT | 2002 |
Prenatal diagnosis and treatment of fetal long QT syndrome: a case report.
Topics: Adult; Bradycardia; Bundle-Branch Block; Electrocardiography; Female; Fetal Diseases; Heart Block; H | 2002 |
Cardiotoxicity associated with intentional ziprasidone and bupropion overdose.
Topics: Adolescent; Anti-Arrhythmia Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; | 2003 |
Prenatal diagnosis and in utero treatment of torsades de pointes associated with congenital long QT syndrome.
Topics: Adult; Anti-Arrhythmia Agents; Echocardiography; Electrocardiography; Female; Fetal Diseases; Gestat | 2003 |
A novel mutation in SCN5A, delQKP 1507-1509, causing long QT syndrome: role of Q1507 residue in sodium channel inactivation.
Topics: Adult; Base Sequence; Cell Line; Child; Chromatography, High Pressure Liquid; DNA Mutational Analysi | 2003 |
Utility of a simplified lidocaine and potassium infusion in diagnosing long QT syndrome among patients with borderline QTc interval prolongation.
Topics: Adult; Case-Control Studies; Electrocardiography; Female; Humans; Infusions, Intravenous; Lidocaine; | 2004 |
A novel SCN5A mutation manifests as a malignant form of long QT syndrome with perinatal onset of tachycardia/bradycardia.
Topics: Bradycardia; Cell Line; DNA Mutational Analysis; Female; Humans; Infant, Newborn; Lidocaine; Long QT | 2004 |
[Anesthetic management of caesarean section in a patient with asymptomatic idiopathic prolonged QT interval syndrome].
Topics: Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Anesthesia, Spinal; Bupivacaine; Cesarean Sect | 2004 |
Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.
Topics: Acetanilides; Action Potentials; Anesthetics, Local; Animals; Anti-Arrhythmia Agents; Binding Sites; | 2006 |
Neonatal life-threatening arrhythmia responding to lidocaine, a probable LQTS3.
Topics: Anti-Arrhythmia Agents; Humans; Infant, Newborn; Lidocaine; Long QT Syndrome; Male; Torsades de Poin | 2007 |
Transient alterations in transmural repolarization gradients and arrhythmogenicity in hypokalaemic Langendorff-perfused murine hearts.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Electrophysiology; Endocardium; Heart; Hypokalem | 2007 |
Combination of cardiac conduction disease and long QT syndrome caused by mutation T1620K in the cardiac sodium channel.
Topics: Action Potentials; Adolescent; Adult; Ajmaline; Animals; Anti-Arrhythmia Agents; Bundle-Branch Block | 2008 |
Lidocaine block of LQT-3 mutant human Na+ channels.
Topics: Anti-Arrhythmia Agents; Cell Line; Electric Conductivity; Gene Deletion; Humans; Lidocaine; Long QT | 1996 |
Phenotypic characterization of a novel long-QT syndrome mutation (R1623Q) in the cardiac sodium channel.
Topics: Animals; Anti-Arrhythmia Agents; CHO Cells; Cricetinae; Cricetulus; Female; Genes, Dominant; Humans; | 1998 |
Selective block of late currents in the DeltaKPQ Na(+) channel mutant by pilsicainide and lidocaine with distinct mechanisms.
Topics: Animals; Anti-Arrhythmia Agents; Cells, Cultured; Cricetinae; Electrophysiology; Humans; Lidocaine; | 2000 |
Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?
Topics: Anti-Arrhythmia Agents; Case-Control Studies; Electrocardiography; Female; Flecainide; Heart; Hetero | 2000 |
Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?
Topics: Anti-Arrhythmia Agents; Case-Control Studies; Electrocardiography; Female; Flecainide; Heart; Hetero | 2000 |
Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?
Topics: Anti-Arrhythmia Agents; Case-Control Studies; Electrocardiography; Female; Flecainide; Heart; Hetero | 2000 |
Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?
Topics: Anti-Arrhythmia Agents; Case-Control Studies; Electrocardiography; Female; Flecainide; Heart; Hetero | 2000 |
A revised view of cardiac sodium channel "blockade" in the long-QT syndrome.
Topics: Animals; Anti-Arrhythmia Agents; Cell Line; Electrophysiology; Humans; Ion Channel Gating; Lidocaine | 2000 |
[Long QT syndrome and regional anesthesia. Apropos of a case].
Topics: Adjuvants, Anesthesia; Adolescent; Anesthesia, Spinal; Anesthetics, Local; Arrhythmias, Cardiac; Dis | 2000 |
Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome.
Topics: Anti-Arrhythmia Agents; Cell Line; Dose-Response Relationship, Drug; Flecainide; Genetic Linkage; Hu | 2000 |
[QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
Topics: Aged; Anti-Arrhythmia Agents; Antidepressive Agents, Second-Generation; Coronary Angiography; Diagno | 2001 |
Role of early afterdepolarization in familial long QTU syndrome and torsade de pointes.
Topics: Action Potentials; Adolescent; Cardiac Pacing, Artificial; Epinephrine; Female; Heart Conduction Sys | 1992 |
Torsades de pointes and ventricular fibrillation in a canine model of quinidine-induced QT prolongation.
Topics: Animals; Bretylium Tosylate; Cardiac Pacing, Artificial; Dogs; Female; Heart Conduction System; Isop | 1992 |
[Long-term treatment of ventricular arrhythmia caused by electrocardiographic long QT syndrome].
Topics: Arrhythmias, Cardiac; Atropine; Autonomic Nerve Block; Cardiac Complexes, Premature; Child; Combined | 1988 |
[Blockade of the left stellate ganglion. Treatment of ventricular arrhythmias in secondary QT prolongation].
Topics: Adult; Arrhythmias, Cardiac; Female; Heart Ventricles; Humans; Lidocaine; Long QT Syndrome; Male; Mi | 1986 |